(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing … Continued
(July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This rating, the highest awarded by Charity Navigator, demonstrates OCRFA’s continued commitment to maintaining responsible fiscal management practices, as well as transparency and accountability, as we continue to strive toward a cure for ovarian … Continued
(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.
(June 30, 2017) Ten thousand women, most of whom are BRCA1 or BRCA2 positive, were analyzed by the University of Cambridge in order to find age specific risk for breast and ovarian cancers. The goal of the study, which was published in the Journal of the American Medical Association (JAMA), was to better enable clinicians … Continued
(June 23, 2017) A clinical trial published in the Journal of Clinical Oncology focused on a largely understudied area of cancer survivorship: chemotherapy-induced peripheral neuropathy (CIPN) in women. Forty seven percent of the 512 women in the trial reported CIPN an average of 6 years after their treatment ended. Symptoms of CIPN reported during the … Continued
According to recent reports, the Department of Health and Human Services (HHS) will soon seek to limit access to oral contraception benefits. “The proposed rule allowing employers to deny insurance coverage for birth control limits the application of oral contraceptives in preventive medicine, in particular, for ovarian cancer. Oral contraceptives have been shown to reduce … Continued
(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long term survivors of advanced stage ovarian cancer. Woman surviving 8.5 years or longer, who had anywhere from 0 recurrences to multiple recurrences, were given surveys … Continued
The White House has released a proposed budget for FY2018 that makes drastic cuts to the budgets for the National Institute of Health (NIH) and Centers for Disease Control and Prevention (CDC). These cuts would reduce the NIH budget by 20% and threaten to halt breakthrough medical research advancements and delay life-saving cures. The proposed … Continued
(May 25, 2017) A retrospective study, published earlier this month in Obstetrics & Gynecology, looked at when women with ovarian cancer developed blood clots. One in four women diagnosed with ovarian cancer develop a blood clot, but more specifically, over eleven percent of those who developed a blood clot did so during neoadjuvant chemotherapy. Women … Continued
(May 22, 2017) A recent study from the Netherlands found that a combination of cognitive behavior therapies had a positive effect on FCR, or Fear of Cancer Recurrence. Eighty-eight cancer survivors, including breast, prostate, and colorectal cancers, were divided into either a control group, which received usual care, or the therapy group. The participants that received … Continued
(May 2, 2017) A study, published in Gynecologic Oncology, revealed the importance of tumor antigen NY-ESO-1 for ovarian cancer patients. This tumor antigen, although not normally found in healthy cells, is very prevalent in tumors such as epithelial ovarian cancers. Over the course of the 14 year study, Roswell Park tested 1,000 ovarian cancer patients … Continued
(April 26, 2017) A study recently published in Cancer evaluates the effect that cediranib, a drugs that stops the growth of new blood vessels, has on a patient’s quality of life (QOL) when used as maintenance therapy. Previous studies have shown that, for patients with relapsed epithelial ovarian cancer, cediranib used as maintenance therapy can … Continued
Get email updates about research news, action alerts, and ways to join the fight.
